Skip to content

real world experience

Shackelford Pharma is built on Dr. Shackelford's real world experience and insights. This represents over 27,000 real patient interactions with real outcomes. Shackelford's team has analyzed patient outcomes to identify the most promising therapeutic candidates for development. Shackelford Pharma has exclusive access to these insights.

Our therapeutic focus

Shackelford is focused on epilepsy. Our drug candidate (SP1707) is supported by decades of patient treatment years of data from patients under the care of Dr. Shackelford. Our mission is to bring this new medicine through the development and FDA regulatory process to benefit people with epilepsy with unmet medical needs.

World-Class
Team

Our world-class R&D team has over 320 years of collective pharmaceutical drug development experience. All have enjoyed key leadership roles in the development of 43 drugs that have been approved by the FDA. This includes 7 which have sold over $1B per year and 6 anti-epileptic drugs.

"Dr. Shackelford . . . has developed what many in the industry consider the most advanced database. Now his patience (and his patients) are being rewarded."

- FORBES

Shackelford Pharma Executives Mark Godsy and Dr. Alan Shackelford to Present Promising Data on Neurological Treatment, Hosted by Dr. David Sans at EF Hutton

October 15, 2024
Vancouver BC, Canada (October 24, 2024) — Shackelford Pharma Inc. (“Shackelford” or the “Company”), a pharmaceutical company developing medicines for neurological diseases with significant unmet patient needs, is pleased to
Read More

Shackelford Pharma Inc. Announces Positive Data from Retrospective Analysis

February 6, 2023
Vancouver BC, Canada (February 6, 2023) — Shackelford Pharma Inc. (“Shackelford” or the “Company”), a pharmaceutical company developing medicines for neurological diseases with significant unmet patient needs, is pleased to
Read More

Shackelford Pharma Congratulates Team & SAB Members on Publication

November 21, 2022
Shackelford Pharma congratulates O’Neill D’Cruz, a member of Shackelford’s clinical development team, and our Scientific Advisory Board Members Emilio Perucca and Jeffrey Buchhalter, co-authors of the article “EEG Parameters as
Read More
Invest in Shackelford

Shackelford Pharma’s Regulation A Financing is now open. Investors are required to fill out the form below to begin the investment process.

Please check your JUNK/SPAM email folder if your invitation email from Dealmaker/Shackelford does not arrive in your inbox.

Invest Shackelford